Treatment of chemokine mediated diseases
View Patent ↗Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
1. A method of treating rheumatoid arthritis comprising administering to a patient in need of such treatment, a therapeutically effective amount of:
(a) a compound of the formula
or a pharmaceutically acceptable salt thereof; and
(b) one or more drugs, agents or therapeutics selected from the group consisting of;
(i) a disease modifying antirheumatic drug;
(ii) a nonsteroidal anti-inflammatory drug;
(iii) a COX-2 selective inhibitor;
(iv) a COX-1 inhibitor;
(v) an immunosuppressive;
(vi) a steroid;
(vii) a biological response modifier and
(viii) an other anti-inflammatory agent or therapeutic.
2. The method of claim 1 wherein said compound is a calcium or sodium salt.
3. The method of claim 1 wherein said one or more drugs, agents or therapeutics is a disease modifying antirheumatic drug selected from the group consisting of methotrexate, azathioprine, leflunomide, penicillamine, a gold salt, mycophenolate, mofetil and cyclophosphamide.
4. The method of claim 1 wherein said one or more drugs, agents or therapeutics is a nonsteroidal anti-inflammatory drug selected from the group consisting of piroxicam, ketoprofen, naproxen, indomethacin, and ibuprofen.
5. The method of claim 1 wherein said one or more drugs, agents or therapeutics is a COX-2 selective inhibitor selected from the group consisting of rofecoxib and celecoxib.
6. The method of claim 1 wherein said one or more drugs, agents or therapeutics is a COX-1 inhibitor, which is piroxicam.
7. The method of claim 1 wherein said one or more drugs, agents or therapeutics is an immunosuppressive selected from the group consisting of methotrexate, cyclosporin, leflunimide, tacrolimus, rapamycin and sulfasalazine.
8. The method of claim 1 wherein said one or more drugs, agents or therapeutics is a steroid selected from the group consisting of β-methasone, prednisone, cortisone, prednisolone and dexamethasone.
9. The method of claim 1 wherein said one or more drugs, agents or therapeutics is a biological response modifier selected from the group consisting of an anti-TNF antagonist, an IL-1 antagonist, an anti-CD40 molecule, an anti-CD28 molecule, IL-10 molecule and an anti-adhesion molecule.
10. The method of claim 1 wherein said other anti-inflammatory agents or therapeutics are selected from the group consisting of a p38 kinase inhibitor, a PDE4 inhibitor, a TACE inhibitor, a chemokine receptor antagonist, thalidomide, and a leukotriene inhibitor.
11. The method of claim 1 wherein said one or more drugs, agents or therapeutics are selected from the group consisting of a COX-2 selective inhibitor, an immunosuppressive, and a steroid.